On July 14, HCA Healthcare fell 4.73% in pre-market trading, trading at approximately $372.26 per share, with turnover of $283,500.

The decline extends a period of sustained selling pressure driven by a wave of analyst downgrades. Multiple Wall Street banks have recently cut their price targets on HCA: Mizuho lowered its target from $585 to $525 while maintaining an Outperform rating; Barclays downgraded the stock from Overweight to Equal Weight, slashing its target from $496 to $427; Stephens reduced its target from $530 to $500; and Cantor Fitzgerald cut from $588 to $525. The FactSet consensus average target price has fallen from approximately $546 at the start of the year to roughly $492.60, a cumulative reduction of nearly 10%.

Fundamentally, the company reported that Q1 did not see its traditional seasonal volume growth, with mild respiratory disease activity and winter storms reducing adjusted EBITDA by approximately $180 million. The broader Health Care Facilities sector remains under pressure, with Tenet Healthcare down 2.67% and Universal Health Services down 0.80%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)